
Selective protein separation based mostly on cost anisotropy by spherical polyelectrolyte brushes
Protein purification is of significant significance within the meals business, drug discovery and different associated fields. Amongst many separation strategies, polyelectrolyte (PE)-based section separation is developed and acknowledged as a low-cost purification approach. On this work, spherical polyelectrolyte brushes (SPBs) with excessive particular floor space was utilized to review the protein accessibility and selective protein binding on extremely charged nanoparticles (NPs) in addition to the selective section separation of proteins.
The correlation between cost anisotropy, protein binding, and section separation was investigated on numerous protein programs together with these proteins with comparable isoelectric factors (pI) similar to bovine serum albumin (BSA) and β-lactoglobulin (BLG), proteins with comparable molecular weights similar to BSA and hemoglobin (HB), and even protein variants (BLG-A and -B) with tiny distinction of amino acids.
The non-specific electrostatic interplay studied by turbidimetric titrations and isothermal calorimetry titration (ITC) signifies a particular binding between proteins and SPBs arising from the cost anisotropy of proteins.
An optimized output based mostly on selective protein binding on SPBs may very well be correlated for environment friendly protein separation by tuning exterior situations together with pH and ionic power. These findings due to this fact proved that section separation based mostly on selective protein adsorption by SPBs was an environment friendly various for proteins separation in contrast with conventional follow.
Reengineering anthrax toxin protecting antigen for improved receptor-specific protein supply
Background: To extend the scale of the druggable proteome, it will be extremely fascinating to plan environment friendly strategies to translocate designed binding proteins to the cytosol, as they might particularly goal flat and hydrophobic protein-protein interfaces.
If this may very well be carried out in a fashion depending on a cell floor receptor, two layers of specificity could be obtained: one for the cell sort and the opposite for the cytosolic goal. Bacterial protein toxins have naturally developed such programs.
Anthrax toxin consists of a pore-forming translocation unit (protecting antigen (PA)) and a separate protein payload. When engineering PA to ablate binding to its personal receptor and as an alternative binding to a receptor of alternative, by fusing a designed ankyrin repeat protein (DARPin), uptake in new cell varieties will be achieved.
Outcomes: Prepore-to-pore conversion of redirected PA already happens on the cell floor, limiting the quantity of PA that may be administered and thus limiting the quantity of delivered payload. We hypothesized that the reason being a scarcity of a stabilizing interplay with wild-type PA receptor.
We’ve got now reengineered PA to include the binding area of the anthrax receptor CMG2, adopted by a DARPin, binding to the receptor of alternative. This assemble is certainly stabilized, undergoes prepore-to-pore conversion solely in late endosomes, will be administered to a lot greater concentrations with out displaying toxicity, and consequently delivers a lot greater quantities of payload to the cytosol.
Conclusion: We imagine that this reengineered system is a vital step ahead to addressing environment friendly cell-specific supply of proteins to the cytosol.
Key phrases: Anthrax toxin; Cytosolic protein supply; DARPin; Protecting antigen.

choleratox
Amylin Blocking Peptide |
|||
20-abx062762 | Abbexa |
|
|
Amylin Blocking Peptide |
|||
DF7715-BP | Affbiotech | 1mg | EUR 234 |
Borrelia Vmp-like sequence expressed (VlsE) C6 peptide (>90%) for ELISA |
|||
VLSE65-UL | Alpha Diagnostics | 100 ug | EUR 416.4 |
Borrelia Vmp-like sequence expressed (VlsE) C6 peptide-Biotin (>90%) for ELISA |
|||
VLSE65-BTN | Alpha Diagnostics | 100 ug | EUR 489.6 |
Rabbit Anti-Borrelia Vmp-like sequence expressed (VlsE) C6 peptide IgG, aff pure |
|||
VLSE61-A | Alpha Diagnostics | 100 ul | EUR 578.4 |
Influenza A virus (H5N1) matrix protein 2 hybrid sequence Control/blocking peptide |
|||
M2E11-P | Alpha Diagnostics | 100 ug | EUR 196.8 |
Rat Amylin Control/blocking peptide # 3 |
|||
AMYL13-P | Alpha Diagnostics | 100 ug | EUR 196.8 |
Human Amylin Control/blocking peptide # 2 |
|||
AMYL12-P | Alpha Diagnostics | 100 ug | EUR 196.8 |
Human Amylin (1-37 aa) Control/blocking peptide #1 |
|||
AMYL11-P | Alpha Diagnostics | 100 ug | EUR 196.8 |
HIV 2 gp36 envelope antigen. Synthetic HIV-2 Peptide containing the HIV-2 specific sequence of gp36. |
|||
00180-V-100ugvial | Virogen | 100ug/vial | EUR 150 |
Description: HIV 2 gp36 envelope antigen. Synthetic HIV-2 Peptide containing the HIV-2 specific sequence of gp36. |
Human, mouse, rat connexin 43 and 37 hemi-channel blocking peptide (GAP27 domain with conserved sequence SRPTEK) |
|||
Cx2703-P-1 | Alpha Diagnostics | 1 mg | EUR 315.6 |
Human, mouse, rat connexin 43 and 37 hemi-channel blocking peptide (GAP27 domain with conserved sequence SRPTEK) |
|||
Cx2703-P-5 | Alpha Diagnostics | 5 mg | EUR 927.6 |
HIV type O envelope antigen. Synthetic HIV type-O peptide, containing the HIV type-O envelope-derived sequence. |
|||
00178-V-100ugvial | Virogen | 100ug/vial | EUR 150 |
Description: HIV type O envelope antigen. Synthetic HIV type-O peptide, containing the HIV type-O envelope-derived sequence. |
Anantin (linear sequence) |
|||
5-00672 | CHI Scientific | 4 x 1mg | Ask for price |
C5a Inhibitory Sequence |
|||
H-8135.0005 | Bachem | 5.0mg | EUR 849.6 |
Description: Sum Formula: C51H86N12O9; CAS# [133214-60-5] |
C5a Inhibitory Sequence |
|||
H-8135.0025 | Bachem | 25.0mg | EUR 3286.8 |
Description: Sum Formula: C51H86N12O9; CAS# [133214-60-5] |
Anantin (linear sequence) |
|||
H-8140.0001 | Bachem | 1.0mg | EUR 691.2 |
Description: Sum Formula: C90H113N21O25; CAS# [348600-37-3] net |
Anantin (linear sequence) |
|||
H-8140.0005 | Bachem | 5.0mg | EUR 2648.4 |
Description: Sum Formula: C90H113N21O25; CAS# [348600-37-3] net |
LL - 37, reverse sequence |
|||
5-01471 | CHI Scientific | 4 x 1mg | Ask for price |
ACES™ Signal Sequence Kit |
|||
0148-2 | AthenaES | kit | EUR 373.2 |
Substance P reversed sequence |
|||
5-01970 | CHI Scientific | 4 x 5mg | Ask for price |
a2b1 Integrin Recognition Sequence |
|||
H-1376.0025 | Bachem | 25.0mg | EUR 691.2 |
Description: Sum Formula: C14H22N4O9; CAS# [134580-64-6] |
a2b1 Integrin Recognition Sequence |
|||
H-1376.0100 | Bachem | 100.0mg | EUR 1995.6 |
Description: Sum Formula: C14H22N4O9; CAS# [134580-64-6] |
Synthetic HIV-2 gp 36 Sequence |
|||
VAng-0535Lsx-inquire | Creative Biolabs | inquire | Ask for price |
Description: HIV type 2 glycoprotein 36, chemically synthesized polypeptide containing immunodominant region of the HIV-2 envelope. 1.00 mg/mL. |
Signal Sequence Receptor, beta Antibody |
|||
20-abx137475 | Abbexa |
|
|
Breast Carcinoma Amplified Sequence 2 |
|||
PR27246 | Neuromics | 5 ug | EUR 381.6 |
LL-37, reverse sequence (synthetic >95%) |
|||
SP-88325-1 | Alpha Diagnostics | 1 mg | EUR 416.4 |
Signal Sequence Receptor, alpha Antibody |
|||
20-abx115551 | Abbexa |
|
|
Anti-Signal sequence receptor delta (2D3) |
|||
YF-MA15624 | Abfrontier | 100 ug | EUR 435.6 |
Description: Mouse monoclonal to Signal sequence receptor delta |
TPA-Induced Sequence 11b (TIS11B) Antibody |
|||
20-abx219410 | Abbexa |
|
|
G-Rich Sequence Factor 1 (GRSF1) Antibody |
|||
abx340117-100ug | Abbexa | 100 ug | EUR 469.2 |
Signal Sequence Receptor Delta (SSR4) Antibody |
|||
20-abx137478 | Abbexa |
|
|
Signal Sequence Receptor Alpha (SSRa) Antibody |
|||
20-abx131611 | Abbexa |
|
|
Neuroblastoma Amplified Sequence (NBAS) Antibody |
|||
abx235565-100ug | Abbexa | 100 ug | EUR 610.8 |
Neuroblastoma Amplified Sequence (NBAS) Antibody |
|||
20-abx217051 | Abbexa |
|
|
Neuroblastoma Amplified Sequence (NBAS) Antibody |
|||
20-abx321319 | Abbexa |
|
|
Neuroblastoma Amplified Sequence (NBAS) Antibody |
|||
20-abx114066 | Abbexa |
|
|
Neuroblastoma Amplified Sequence (NBAS) Antibody |
|||
20-abx003586 | Abbexa |
|
|
Amylin/ Rat Amylin ELISA Kit |
|||
ELA-E0812r | Lifescience Market | 96 Tests | EUR 1063.2 |
Glioblastoma-Amplified Sequence (GBAS) Antibody |
|||
abx146091-100ug | Abbexa | 100 ug | EUR 469.2 |
Glioblastoma-Amplified Sequence (GBAS) Antibody |
|||
abx032970-400ul | Abbexa | 400 ul | EUR 627.6 |
Glioblastoma-Amplified Sequence (GBAS) Antibody |
|||
abx032970-80l | Abbexa | 80 µl | EUR 343.2 |
Human Amylin(Amylin)ELISA Kit |
|||
YLA1491HU-48T | Shanghai YL Biotech | 48T | EUR 435 |
Human Amylin(Amylin)ELISA Kit |
|||
YLA1491HU-96T | Shanghai YL Biotech | 96T | EUR 562.5 |
Testis-expressed sequence 12 protein Antibody |
|||
20-abx110259 | Abbexa |
|
|
Single Cell Sequence Specific Amplification Kit |
|||
P621-01 | Vazyme | 200 rxn | EUR 314.4 |
Recombinant Signal Sequence Receptor Alpha (SSRa) |
|||
4-RPC871Hu01 | Cloud-Clone |
|
|
Description: Recombinant Human Signal Sequence Receptor Alpha expressed in: E.coli |
HIV Protease Substrate III-B (Native Sequence) |
|||
H-9650.0001 | Bachem | 1.0mg | EUR 135.6 |
Description: Sum Formula: C51H90N18O14S; CAS# [179912-80-2] |
HIV Protease Substrate III-B (Native Sequence) |
|||
H-9650.0005 | Bachem | 5.0mg | EUR 385.2 |
Description: Sum Formula: C51H90N18O14S; CAS# [179912-80-2] |
HIV Protease Substrate III-B (Native Sequence) |
|||
H-9650.0025 | Bachem | 25.0mg | EUR 1402.8 |
Description: Sum Formula: C51H90N18O14S; CAS# [179912-80-2] |
Myeloid Cell Leukemia Sequence 1 (MCL1) Antibody |
|||
abx235053-100ug | Abbexa | 100 ug | EUR 661.2 |
Myeloid Cell Leukemia Sequence 1 (MCL1) Antibody |
|||
abx431424-200ul | Abbexa | 200 ul | EUR 460.8 |
Myeloid Cell Leukemia Sequence 1 (MCL1) Antibody |
|||
20-abx009004 | Abbexa |
|
|
Amylin |
|||
B5423-10 | ApexBio | 10 mg | EUR 525.6 |
Amylin |
|||
B5423-50 | ApexBio | 50 mg | EUR 1695.6 |
Human Testis- expressed sequence 264 protein, TEX264 ELISA KIT |
|||
ELI-28287h | Lifescience Market | 96 Tests | EUR 988.8 |
Human G- rich sequence factor 1, GRSF1 ELISA KIT |
|||
ELI-39072h | Lifescience Market | 96 Tests | EUR 988.8 |
Mouse G- rich sequence factor 1, Grsf1 ELISA KIT |
|||
ELI-42875m | Lifescience Market | 96 Tests | EUR 1038 |
Human Signal Sequence Receptor Alpha (SSRa) Protein |
|||
20-abx650225 | Abbexa |
|
|
human similar to cDNA sequence BC027382 ELISA Kit |
|||
201-12-1889 | SunredBio | 96 tests | EUR 528 |
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids. |
Human similar to cDNA sequence BC027382 ELISA Kit |
|||
GA-E1905HM-48T | GenAsia Biotech | 48T | EUR 346.8 |
Human similar to cDNA sequence BC027382 ELISA Kit |
|||
GA-E1905HM-96T | GenAsia Biotech | 96T | EUR 559.2 |
Human similar to cDNA sequence BC027382 ELISA Kit |
|||
QY-E02390 | Qayee Biotechnology | 96T | EUR 433.2 |
human similar to cDNA sequence BC027382 ELISA Kit |
|||
YLA2833HU-48T | Shanghai YL Biotech | 48T | EUR 435 |
human similar to cDNA sequence BC027382 ELISA Kit |
|||
YLA2833HU-96T | Shanghai YL Biotech | 96T | EUR 562.5 |
Mouse G-Rich Sequence Factor 1 (GRSF1) ELISA Kit |
|||
abx389463-96tests | Abbexa | 96 tests | EUR 1093.2 |
Human G-Rich Sequence Factor 1 (GRSF1) ELISA Kit |
|||
abx384974-96tests | Abbexa | 96 tests | EUR 1093.2 |
Malignant T-Cell-Amplified Sequence 1 Protein |
|||
20-abx261032 | Abbexa |
|
|
Human Testis-expressed sequence 12 protein (TEX12) |
|||
1-CSB-EP023402HU | Cusabio |
|
|
Description: Recombinant Human Testis-expressed sequence 12 protein(TEX12) expressed in E.coli |
Natural Killer-Tumor Recognition Sequence Antibody |
|||
20-abx114028 | Abbexa |
|
|
Testis-expressed sequence 12 protein Antibody (HRP) |
|||
20-abx108804 | Abbexa |
|
|
Signal Sequence Receptor Subunit Delta (SSR4) Antibody |
|||
abx238249-100ug | Abbexa | 100 ug | EUR 661.2 |
Family With Sequence Similarity 119A (FAM119A) Antibody |
|||
abx232959-100ug | Abbexa | 100 ug | EUR 610.8 |
Family With Sequence Similarity 120A (FAM120A) Antibody |
|||
abx232960-100ug | Abbexa | 100 ug | EUR 610.8 |
Testis-expressed sequence 12 protein Antibody (FITC) |
|||
20-abx107384 | Abbexa |
|
|
Family With Sequence Similarity 120A (FAM120A) Antibody |
|||
20-abx112431 | Abbexa |
|
|
Signal Sequence Receptor Subunit Delta (SSR4) Antibody |
|||
20-abx115553 | Abbexa |
|
|
Family With Sequence Similarity 120A (FAM120A) Antibody |
|||
20-abx002424 | Abbexa |
|
|
Human Breast carcinoma-amplified sequence 1 (BCAS1) |
|||
1-CSB-YP002596HU | Cusabio |
|
|
Description: Recombinant Human Breast carcinoma-amplified sequence 1(BCAS1) expressed in Yeast |
Human Breast carcinoma-amplified sequence 1 (BCAS1) |
|||
1-CSB-EP002596HU | Cusabio |
|
|
Description: Recombinant Human Breast carcinoma-amplified sequence 1(BCAS1) expressed in E.coli |
Family with Sequence Similarity 19 Member A2 Protein |
|||
20-abx260703 | Abbexa |
|
|
Impact of methotrexate therapy on the expression of epidermal-fatty acid-binding protein (E-FABP) and apolipoproteins in sufferers with psoriasis
Introduction: Epidermal-fatty acid-binding protein (E-FABP) is a marker of transiently amplifying cells that are fashioned from stem cells in dermis. Their position is an uptake of fatty acids and metabolism. Psoriatic keratinocytes overexpress E-FABPs, which ends up in acanthosis and will clarify the lipid’s disturbances in psoriasis.
Purpose: Evaluation of FABP and apolipoprotein expression in sufferers handled with methotrexate (MTX).
Materials and strategies: FABP expression within the lesional and perilesional psoriatic pores and skin from 11 male sufferers in comparison with 5 wholesome pores and skin samples had been evaluated by immunohistochemistry. FABP, apolipoprotein A1 (ApoA1) and B (ApoB) serum ranges had been assessed by ELISA. These parameters had been evaluated earlier than and after therapy with subcutaneous MTX (15 mg/wk for 12 weeks).
Outcomes: Expression of E-FABP was decrease within the management group than within the lesional and perilesional psoriatic pores and skin, earlier than and after therapy. After therapy the expression decreased within the lesional and perilesional pores and skin. Serum E-FABP was greater within the management group (482.855 ±240.550 pg/ml) in comparison with sufferers, however not statistically considerably.
After MTX therapy, a statistically important discount was noticed in psoriatic sufferers. ApoA1 ranges didn’t differ within the management and sufferers teams, each earlier than and after therapy. In distinction, ApoB ranges didn’t differ statistically between the management group (1447.126 ±311.11 ng/ml) and sufferers earlier than therapy, whereas they had been the bottom after therapy (1081.67 ±117.83 ng/ml vs. 808.306 ±103.72 ng/ml; p < 0.01).
Conclusions: Our examine confirms the useful impact of MTX, not solely as an anti-proliferative impact, but in addition lowering the cardiovascular danger by lowering atherogenic ApoB.
Key phrases: apolipoprotein; fatty acid-binding protein; methotrexate; psoriasis.
Nucleolar Protein 3 (NOL3) Antibody (HRP) |
|||
20-abx304651 | Abbexa |
|
|
Nucleolar Protein 3 (NOL3) Antibody (FITC) |
|||
20-abx304652 | Abbexa |
|
|
Nucleolar Protein 3 (NOL3) Antibody (Biotin) |
|||
20-abx304653 | Abbexa |
|
|
Nucleolar protein 58 Antibody (HRP) |
|||
20-abx108572 | Abbexa |
|
|
Nucleolar protein 58 Antibody (FITC) |
|||
20-abx107151 | Abbexa |
|
|
Nucleolar Protein 4 (NOL4) Antibody |
|||
abx235785-100ug | Abbexa | 100 ug | EUR 577.2 |
Nucleolar Protein 6 (NOL6) Antibody |
|||
abx235786-100ug | Abbexa | 100 ug | EUR 577.2 |
Nucleolar Protein 6 (NOL6) Antibody |
|||
abx235787-100ug | Abbexa | 100 ug | EUR 610.8 |
Nucleolar Protein 8 (NOL8) Antibody |
|||
abx235788-100ug | Abbexa | 100 ug | EUR 610.8 |
Nucleolar Protein 9 (NOL9) Antibody |
|||
abx235789-100ug | Abbexa | 100 ug | EUR 661.2 |
Nucleolar Protein 4 (NOL4) Antibody |
|||
20-abx217203 | Abbexa |
|
|
Nucleolar Protein 8 (NOL8) Antibody |
|||
20-abx217204 | Abbexa |
|
|
Nucleolar Protein 7 (NOL7) Antibody |
|||
20-abx217284 | Abbexa |
|
|
Nucleolar Protein 9 (NOL9) Antibody |
|||
20-abx211330 | Abbexa |
|
|
Nucleolar Protein 8 (NOL8) Antibody |
|||
20-abx141132 | Abbexa |
|
|
Nucleolar Protein 9 (NOL9) Antibody |
|||
abx122121-100ug | Abbexa | 100 ug | EUR 469.2 |
Nucleolar Protein 8 (NOL8) Antibody |
|||
20-abx324504 | Abbexa |
|
|
Nucleolar Protein 8 (NOL8) Antibody |
|||
20-abx114219 | Abbexa |
|
|
Nucleolar Protein 9 (NOL9) Antibody |
|||
abx034569-400ul | Abbexa | 400 ul | EUR 627.6 |
Nucleolar Protein 9 (NOL9) Antibody |
|||
abx034569-80l | Abbexa | 80 µl | EUR 343.2 |
Nucleolar Protein 4 (NOL4) Antibody |
|||
abx029414-400ul | Abbexa | 400 ul | EUR 627.6 |
Nucleolar Protein 4 (NOL4) Antibody |
|||
abx029414-80l | Abbexa | 80 µl | EUR 343.2 |
Nucleolar Protein 9 (NOL9) Antibody |
|||
20-abx124786 | Abbexa |
|
|
Nucleolar Protein 6 (NOL6) Antibody |
|||
20-abx301690 | Abbexa |
|
|
NOP2 Antibody / Nucleolar protein 2 |
|||
F53988-0.05ML | NSJ Bioreagents | 0.05 ml | EUR 140.25 |
Description: Nucleolar protein 2 is an S-adenosyl-L-methionine-dependent methyltransferase that specifically methylates the C(5) position of cytosine 4447 in 28S rRNA (Probable). May play a role in the regulation of the cell cycle and the increased nucleolar activity that is associated with the cell proliferation. |
NOP2 Antibody / Nucleolar protein 2 |
|||
F53988-0.2ML | NSJ Bioreagents | 0.2 ml | EUR 322.15 |
Description: Nucleolar protein 2 is an S-adenosyl-L-methionine-dependent methyltransferase that specifically methylates the C(5) position of cytosine 4447 in 28S rRNA (Probable). May play a role in the regulation of the cell cycle and the increased nucleolar activity that is associated with the cell proliferation. |
Nucleolar protein 58 Antibody (Biotin) |
|||
20-abx105733 | Abbexa |
|
|
Nucleolar Protein 12 (NOL12) Antibody |
|||
abx235783-100ug | Abbexa | 100 ug | EUR 610.8 |
Nucleolar Protein 58 (NOL58) Antibody |
|||
20-abx110057 | Abbexa |
|
|
Nucleolar Protein 11 (NOL11) Antibody |
|||
20-abx217281 | Abbexa |
|
|
Nucleolar Protein 12 (NOL12) Antibody |
|||
20-abx217282 | Abbexa |
|
|
Nucleolar Protein 14 (NOL14) Antibody |
|||
20-abx217283 | Abbexa |
|
|
Nucleolar Protein 10 (NOL10) Antibody |
|||
abx122120-100ug | Abbexa | 100 ug | EUR 469.2 |
Nucleolar Protein 16 (NOP16) Antibody |
|||
abx122144-100ug | Abbexa | 100 ug | EUR 469.2 |
Nucleolar Protein 10 (NOL10) Antibody |
|||
20-abx324613 | Abbexa |
|
|
Nucleolar Protein 12 (NOL12) Antibody |
|||
20-abx114217 | Abbexa |
|
|
Nucleolar Protein 16 (NOP16) Antibody |
|||
abx030640-400ul | Abbexa | 400 ul | EUR 627.6 |
Nucleolar Protein 16 (NOP16) Antibody |
|||
abx030640-80l | Abbexa | 80 µl | EUR 343.2 |
Nucleolar Protein 10 (NOL10) Antibody |
|||
20-abx302728 | Abbexa |
|
|
NOP2 Nucleolar Protein (NOP2) Antibody |
|||
abx235794-100ug | Abbexa | 100 ug | EUR 577.2 |
Nucleolar protein 58 Polyclonal Antibody |
|||
42696-100ul | SAB | 100ul | EUR 399.6 |
Nucleolar Protein 6 (NOL6) Antibody (HRP) |
|||
20-abx311187 | Abbexa |
|
|
Nucleolar Protein 6 (NOL6) Antibody (FITC) |
|||
20-abx311188 | Abbexa |
|
|
Nucleolar Protein 6 (NOL6) Antibody (Biotin) |
|||
20-abx311189 | Abbexa |
|
|
EMG1 Nucleolar Protein Homolog (EMG1) Antibody |
|||
abx232754-100ug | Abbexa | 100 ug | EUR 577.2 |
EMG1 Nucleolar Protein Homolog (EMG1) Antibody |
|||
20-abx112282 | Abbexa |
|
|
EMG1 Nucleolar Protein Homolog (EMG1) Antibody |
|||
abx122814-100ug | Abbexa | 100 ug | EUR 469.2 |
EMG1 Nucleolar Protein Homolog (EMG1) Antibody |
|||
20-abx003301 | Abbexa |
|
|
Nop2 Nucleolar Protein Homolog (Yeast) Antibody |
|||
20-abx114152 | Abbexa |
|
|
Nucleolar Protein 3 (NOL3) Protein |
|||
20-abx260930 | Abbexa |
|
|
Nucleolar protein 58 Polyclonal Conjugated Antibody |
|||
C42696 | SAB | 100ul | EUR 476.4 |
Human Nucleolar protein 3 (NOL3) |
|||
1-CSB-EP015921HU | Cusabio |
|
|
Description: Recombinant Human Nucleolar protein 3(NOL3) expressed in E.coli |
Nucleolar Protein Family 6 (Rna-Associated) Antibody |
|||
20-abx114220 | Abbexa |
|
|
Nucleolar Protein Family A Member 1 (NOLA1) Antibody |
|||
20-abx215552 | Abbexa |
|
|
Nucleolar Protein With MIF4G Domain 1 (NOM1) Antibody |
|||
20-abx121535 | Abbexa |
|
|
Nucleolar Protein With MIF4G Domain 1 (NOM1) Antibody |
|||
20-abx325234 | Abbexa |
|
|
Nucleolar Protein With MIF4G Domain 1 (NOM1) Antibody |
|||
20-abx014679 | Abbexa |
|
|
Guanine Nucleotide Binding Protein Like 3 (Nucleolar) (GNL3) Antibody |
|||
20-abx211238 | Abbexa |
|
|
Guanine Nucleotide Binding Protein Like 3 (Nucleolar) (GNL3) Antibody |
|||
20-abx211323 | Abbexa |
|
|
Guanine Nucleotide Binding Protein Like 3 (Nucleolar) (GNL3) Antibody |
|||
20-abx112902 | Abbexa |
|
|
Guanine Nucleotide Binding Protein Like 3 (Nucleolar) (GNL3) Antibody |
|||
abx031127-400ul | Abbexa | 400 ul | EUR 627.6 |
Guanine Nucleotide Binding Protein Like 3 (Nucleolar) (GNL3) Antibody |
|||
abx031127-80l | Abbexa | 80 µl | EUR 343.2 |
Guanine Nucleotide Binding Protein Like 3 (Nucleolar) (GNL3) Antibody |
|||
abx015873-100ul | Abbexa | 100 ul | EUR 493.2 |
Guanine Nucleotide Binding Protein Like 3 (Nucleolar) (GNL3) Antibody |
|||
abx015874-100ug | Abbexa | 100 ug | EUR 493.2 |
Guanine Nucleotide Binding Protein Like 3 (Nucleolar) (GNL3) Antibody |
|||
20-abx320407 | Abbexa |
|
|
Guanine Nucleotide Binding Protein Like 3 (Nucleolar) (GNL3) Antibody |
|||
20-abx320408 | Abbexa |
|
|
Guanine Nucleotide Binding Protein Like 3 (Nucleolar) (GNL3) Antibody |
|||
abx432758-200ul | Abbexa | 200 ul | EUR 460.8 |
Guanine Nucleotide Binding Protein Like 3 (Nucleolar) (GNL3) Antibody |
|||
abx432759-200ul | Abbexa | 200 ul | EUR 460.8 |
Guanine Nucleotide Binding Protein Like 3 (Nucleolar) (GNL3) Antibody |
|||
20-abx004951 | Abbexa |
|
|
Nucleolar GTP-Binding Protein 1 (GTPBP4) Antibody |
|||
20-abx112873 | Abbexa |
|
|
Nucleolar GTP-binding protein 1 (GTPBP4) Antibody |
|||
20-abx338394 | Abbexa |
|
|
Guanine Nucleotide Binding Protein Like 3 (Nucleolar) Like (GNL3L) Antibody |
|||
20-abx121487 | Abbexa |
|
|
Guanine Nucleotide Binding Protein Like 3 (Nucleolar) Like (GNL3L) Antibody |
|||
20-abx324752 | Abbexa |
|
|
Guanine Nucleotide Binding Protein Like 3 (Nucleolar) Like (GNL3L) Antibody |
|||
abx330979-100ul | Abbexa | 100 ul | EUR 510 |
Guanine Nucleotide Binding Protein Like 3 (Nucleolar) Like (GNL3L) Antibody |
|||
abx026054-400ul | Abbexa | 400 ul | EUR 627.6 |
Guanine Nucleotide Binding Protein Like 3 (Nucleolar) Like (GNL3L) Antibody |
|||
abx026054-80l | Abbexa | 80 µl | EUR 343.2 |
Guanine Nucleotide Binding Protein Like 3 (Nucleolar) Like (GNL3L) Antibody |
|||
20-abx014523 | Abbexa |
|
|
Guanine Nucleotide Binding Protein Like 3 (Nucleolar) Like (GNL3L) Antibody |
|||
20-abx310856 | Abbexa |
|
|
Human Nucleolar Protein 3 (NOL3) ELISA Kit |
|||
abx381839-96tests | Abbexa | 96 tests | EUR 1093.2 |
Human Nucleolar protein 3, NOL3 ELISA KIT |
|||
ELI-36945h | Lifescience Market | 96 Tests | EUR 988.8 |
Mouse Nucleolar protein 3, Nol3 ELISA KIT |
|||
ELI-21222m | Lifescience Market | 96 Tests | EUR 1038 |
Human Nucleolar Protein 3(NOL3)ELISA Kit |
|||
QY-E03192 | Qayee Biotechnology | 96T | EUR 472.8 |
Nucleolar GTP-binding protein 1 (GTPBP4) Antibody (HRP) |
|||
20-abx336862 | Abbexa |
|
|
Nucleolar / Nucleoli(NM95) Antibody |
|||
BNCA0095-250 | Biotium | 250uL | EUR 459.6 |
Description: Primary antibody against Nucleolar / Nucleoli(NM95), APC conjugate, Concentration: 0.1mg/mL |